NeuroVive Pharmaceutical AB Interim Report January – June 2019
Focus on genetic mitochondrial diseases
Press releases
Save the date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019
Lund, 20 August 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company will host a Capital Markets Day in Stockholm on 9 October, 2019, for investors, ...
NeuroVive’s NeuroSTAT project receives FDA Fast Track designation
Lund, Sweden, 27 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company’s candidate drug NeuroSTAT, in development for treatment of moderate to s ...
NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study
Lund, Sweden, 4 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study wit ...
NeuroVive Pharmaceutical AB Interim Report January – March 2019
First subjects enrolled in the KL1333 study
NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA
Lund, Sweden,10 May 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive’s IND (Investigational ...
NeuroVive announces ruling from Supreme Court in case between the company and CicloMulsion AG
Lund, 30 April, 2019— NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the Supreme Court had delivered its ruling concerning arbitration between NeuroVive and Cic ...
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
Lund, Sweden, 25 April 2019, NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) today on 25 April 2019 held its Annual General Meeting (AGM). A summary of the resolutions follows.
Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)
Lund, Sweden, 29 March 2019 - NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announced an increase of the number of shares and votes in NeuroVive of 22,594,467 as a result of ...
NeuroVive Pharmaceutical AB publishes 2018 Annual report
Lund, Sweden, 25 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company’s ...
Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB (publ)
The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, April 25, 2019, at 4 pm at Medicon Village, Scheelev ...
NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study
Lund, Sweden, 19 March 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company’s KL1333 phase Ia/b study has been screen ...